Why microdosing Wegovy is not licensed
Microdosing Wegovy (semaglutide) is not licensed in the UK because it falls outside the doses and treatment schedules approved through clinical trials. Wegovy pens are designed to deliver specific weekly doses to ensure predictable absorption, safety, and effectiveness. Using very small doses over longer periods can lead to inconsistent dosing and reduced treatment reliability.
After first use, Wegovy pens must be used within 6 weeks, regardless of remaining medicine. Microdosing can result in pens being kept and used beyond this timeframe, increasing the risk of reduced potency or contamination. UK regulators and the manufacturer do not support microdosing, and prescribing should always follow licensed Wegovy dosing guidance.
- Microdosing Wegovy is not UK licensed.
- Pens expire 6 weeks after first use, even if medicine remains.
- Extended use may reduce potency and dosing accuracy.
- Pens are designed for approved weekly doses.
- Licensed dosing schedules ensure safe treatment.
This text has been fact checked for accuracy by Sorin Romaniuc, Pharmacist at medino.